SEP 30, 2015 7:30 AM PDT

Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics

Speaker

Abstract

Using the NSGTM mouse (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ), JAX In Vivo Pharmacology Services has combined the human CD34+ hematopoietic stem cell engrafted NSGTM (hu-CD34 NSGTM) with human patient derived xenograft (PDX) to create a platform for humanized preclinical studies in immuno-oncology. Non-HLA matched PDX tumors grow well in hu-CD34 NSGTM, despite concerns over transplant rejection. When unmatched human PDX was engrafted in NSGTM or hu-CD34 NSGTM tumor growth rate was similar, indicating the human immune cells did not influence tumor growth. Next, hu-CD34 NSGTM mice were transplanted with a PDX breast or lung tumor in which 56.9% and 89.1% of the cells in the tumor expressed PD-L1, respectively. When PD-L1 is bound to PD1 on T cells, the T cells are rendered anergic. When treated with Keytruda, an antibody that blocks PD1/PD-L1 binding, tumor growth was significantly diminished. This showed human T cells could be induced to respond to PDX following treatment with a check-point inhibitor. Recognizing that CTL’s are not the only cell population important in immuno-oncology, we are now evaluating NSGTM-SGM3 mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ) for humanization and co-engraftment of PDX. These mice express human IL-3, GM-CSF, and KIT ligand that allow improved development of regulatory T cells (Treg) and myeloid cells. Within the tumor, Treg are implicated in suppression of T effector function. Myeloid derived suppressor cells (MDSC) and tumor associated macrophages (TAM) also diminish immune responses. Engraftment kinetics comparing hu-CD34 NSGTM to hu-CD34 NSGTM-SGM3 hosts show more rapid expansion of CD3+ T cells, Treg, and CD33+ myeloid cells in the NSGTM-SGM3 hosts. Several PDX tumors have successfully engrafted in the hu-CD34 NSGTM-SGM3 hosts, enabling further research into both the basic biology and development of therapeutics in human immuno-oncology.


Show Resources
You May Also Like
APR 28, 2022 8:00 AM PDT
APR 28, 2022 8:00 AM PDT
Date: April 28, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CEST) Human pluripotent stem cells (PSCs) and their derivatives hold great potentials in...
MAY 17, 2022 9:00 AM PDT
MAY 17, 2022 9:00 AM PDT
Date: May 17, 2022 Time: 9:00am (PDT), 12:00pm (EDT), 8:00pm (CEST) Gene therapeutics have great potential to treat many severe diseases in an unprecedented, targeted manner. The biopharmace...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
MAY 19, 2022 8:00 AM PDT
MAY 19, 2022 8:00 AM PDT
Date: May 19, 2022 Time: 8:00am (PDT), 11:00pm (EDT), 5:00pm (CEST) Mass spectrometry (MS)-based proteomic technologies are increasingly applied in a clinical context for disease classific...
MAR 16, 2022 8:00 AM PDT
C.E. CREDITS
MAR 16, 2022 8:00 AM PDT
Date: March 16, 2022 Time: 8:00am (PDT), 11:00am (EDT), 5:00pm (CET) Handling of potent and/or hazardous substances is commonplace in sev.....
JAN 13, 2022 9:00 AM PST
C.E. CREDITS
JAN 13, 2022 9:00 AM PST
Date: January 13, 2022 Time: 09:00am (PST), 12:00pm (EST) Recently, the Infectious Disease Society of America released guidance on how to approach treatment of infections caused by multidrug...
SEP 30, 2015 7:30 AM PDT

Humanized NSGTM Mice for Evaluation of Immuno-Oncology Therapeutics



Show Resources
Loading Comments...
Show Resources